53P - Targeting ER-Golgi homeostasis is an advantageous therapeutic strategy in lung cancer: synergistic interaction of HSP90 antagonist and proteasome in...
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
M. Gottfried1, L. Drucker2, V. Zismanov3
Lung cancer remains the most common cause of cancer-related death worldwide. This malignancy is a complex disease, and it is important to identify potential biological targets, the blockade of which would affect multiple downstream signaling cascades. A growing number of reports recognize novel therapeutic targets in the protein homeostasis network. These include the heat shock protein 90 (Hsp90) essential to posttranslational folding and maturation of multiple oncogenic kinases, and the proteasome that orchestrates the turnover of innumerable cellular proteins. Previous studies demonstrate that targeting Hsp90 or the proteasome separately has anti-non small cell lung cancer (NSCLC) activity. Here, we explored whether combined administration of Hsp90 and proteasome inhibitors promotes the anti-NSCLC activity of the drugs by augmenting disruption of ER-Golgi homeostasis.